<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403725</url>
  </required_header>
  <id_info>
    <org_study_id>MEN1309-01</org_study_id>
    <nct_id>NCT03403725</nct_id>
  </id_info>
  <brief_title>MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study</brief_title>
  <acronym>CD205SHUTTLE</acronym>
  <official_title>Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with&#xD;
      acceptable safety profile and that can be used in patients affected by CD205-positive solid&#xD;
      tumors and Non-Hodgkin Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will investigate the safety and activity of MEN1309 in patients with&#xD;
      CD205-positive metastatic solid tumors and Non-Hodgkin Lymphoma who have tried other types of&#xD;
      treatment for cancer without adequate response (or the cancer came back). CD205 is a protein&#xD;
      present in certain types of cancer.&#xD;
&#xD;
      This is a Phase I study, which means that it is designed to look at several dose levels of a&#xD;
      study drug in small groups of patients to find the dose that is well-tolerated and suitable&#xD;
      to be administered in subsequent clinical trials in patients. The clinical trial is also&#xD;
      looking at the effectiveness of the study drug. This is the first time the study drug will be&#xD;
      given in humans.&#xD;
&#xD;
      The clinical trial consists of two sequential parts:&#xD;
&#xD;
        -  Part 1 involves patients with CD205-positive metastatic solid tumors and the main&#xD;
           purpose of this part of the clinical trial is to determine the highest dose of the study&#xD;
           drug that can be used safely in these type of cancers.&#xD;
&#xD;
        -  Part 2 involves patients with CD205-positive Non-Hodgkin Lymphoma and will test doses of&#xD;
           MEN1309 which have demonstrated to be adequately tolerated in patients with solid&#xD;
           tumors.&#xD;
&#xD;
      Patients participating to the clinical trial will take the study drug as intravenous infusion&#xD;
      once every 3 weeks. The clinical trial includes four periods: a pre-screening period (to&#xD;
      check if tumor is positive for CD205), a screening period (to check whether the participation&#xD;
      to the clinical trial is right for patient), a treatment period (when patient receives the&#xD;
      study drug), and a follow-up period (to check the health status of the patient after stopping&#xD;
      study treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated after achievement of MTD, without progressing to cohort expansion for Company&#xD;
    decision.&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">January 8, 2020</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohort1 0.05mg/kg STEP 1 Solid Tumors Cohort2 0.10mg/kg STEP 1 Solid Tumors Cohort3 0.20mg/kg STEP 1 Solid Tumors Cohort4 0.40mg/kg STEP 1 Solid Tumors Cohort5 0.80mg/kg STEP 1 Solid Tumors Cohort6 1.60mg/kg STEP 1 Solid Tumors Cohort7 2.40mg/kg STEP 1 Solid Tumors Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF Cohort5 0.80mg/kg STEP 2 NHL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-Tolerated Dose (MTD)</measure>
    <time_frame>21-day period after the first dose</time_frame>
    <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences a DLT during the DLT assessment window.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>21-day period after the first dose</time_frame>
    <description>Adverse drug reactions (ADRs) that will be assessed during Cycle 1:&#xD;
any grade ≥ 3 cardiac toxicity, new segmental wall-motion abnormalities, or cardiac troponin I or T elevation of grade 3 or higher;&#xD;
any grade ≥ 3 elevations in total bilirubin, hepatic transaminases, or ALP levels; in patients with baseline grade 2 hepatic transaminase or ALP levels, an elevation to ≥ 10 x ULN is considered a DLT;&#xD;
any grade 3 non-haematologic toxicity lasting &gt; 7 days, (excluding diarrhea/nausea for which no adequate and optimal therapy has been implemented and alopecia);&#xD;
any grade 3 vomiting lasting &gt; 3 days despite adequate and optimal therapy;&#xD;
any grade ≥ 4 non-haematologic toxicity;&#xD;
any grade 4 thrombocytopenia or anemia;&#xD;
any grade 4 neutropenia lasting &gt; 7 days or febrile neutropenia;&#xD;
any treatment delay of &gt; 2 weeks because of delayed recovery from toxicity related to MEN1309 (except for alopecia).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
    <description>Timeframe between the first study drug administration and death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
    <description>The Number of days between the first study administration to the date of first documented disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Tumor Activity (RR)</measure>
    <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
    <description>Preliminary tumor activity (RR) Response Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity (DCR)</measure>
    <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
    <description>Preliminary Antitumor Activity (DCR) Disease control Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity (DOR)</measure>
    <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
    <description>Prliminary Antitumor Activity. Measure of the Duration of response. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 PK Parameter Cmax</measure>
    <time_frame>Cycle 1</time_frame>
    <description>Cmax is the maximum drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 PK Parameter Ctrough</measure>
    <time_frame>Pre-infusion Cycle 2</time_frame>
    <description>MEN1309 PK parameter Ctrough (Predose concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 Pharmacokinetic (PK) Parameter t1/2</measure>
    <time_frame>Cycle 1</time_frame>
    <description>MEN1309 Pharmacokinetic (PK) parameter t1/2 (terminal serum half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 Pharmacokinetic (PK) Parameter AUC</measure>
    <time_frame>Cycle 1</time_frame>
    <description>MEN1309 Pharmacokinetic (PK) parameter AUC (area under curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 (PK) Parameter CL</measure>
    <time_frame>Cycle 1</time_frame>
    <description>Systemic clearance of MEN1309 Pharmacokinetic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEN1309 Pharmacokinetic (PK) Parameter Vd</measure>
    <time_frame>Cycle 1</time_frame>
    <description>volume of distribution based on the terminal phase</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of CD205 Expression in Tumors With Clinical Activity of MEN1309 Assessed According to RECIST 1.1 or Cheson Criteria (2014)</measure>
    <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
    <description>Exploratory Endpoint: Correlation of CD205 expression in tumors with clinical activity of MEN1309 assessed according to RECIST 1.1 or Cheson Criteria (2014) in terms of Response Rate, Disease control rate, duration of response, overall survival, and progression free survival.&#xD;
N.B: No Data were available to assess this outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Anti-MEN1309 Antibodies</measure>
    <time_frame>Day 1 of each Cycle (each cycle is 21 days)</time_frame>
    <description>Exploratory Endpoint: Immunogenicity analysis regarding the Incidence of anti-MEN1309 antibodies.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Metastatic Solid Tumors</condition>
  <condition>Relapsed/Refractory Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.&#xD;
Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEN1309</intervention_name>
    <description>MEN1309 solution for intravenous infusion once every 3 weeks</description>
    <arm_group_label>MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged ≥ 18 years.&#xD;
&#xD;
          2. Patients with:&#xD;
&#xD;
               -  confirmed diagnosis of advanced or metastatic solid tumor and diagnosis of&#xD;
                  multiple relapsed or refractory NHL;&#xD;
&#xD;
               -  progressive after last treatment received;&#xD;
&#xD;
               -  availability of archived tumor material, either as a block or slides;&#xD;
&#xD;
               -  measurable or evaluable disease by Response Evaluation Criteria in solid tumors&#xD;
                  guideline (RECIST v1.1) and by Cheson Criteria (The Lugano Classification, 2014)&#xD;
                  in NHL.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.&#xD;
&#xD;
          4. Neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; haemoglobin ≥ 9 g/dL.&#xD;
&#xD;
          5. Adequate renal and hepatic laboratory assessments.&#xD;
&#xD;
          6. Life expectancy of at least 2 months.&#xD;
&#xD;
          7. Woman of childbearing potential (WOCBP) who agrees to use highly effective&#xD;
             contraception (see Appendix I).&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system involvement (excluding treated stable cerebral metastasis, not&#xD;
             requiring therapy to control symptoms in the last 60 days).&#xD;
&#xD;
          2. Pregnant or breastfeeding women.&#xD;
&#xD;
          3. Life-threatening illnesses other than solid tumors and NHL, uncontrolled medical&#xD;
             conditions or organ system dysfunction which, in the Investigator's opinion, could&#xD;
             compromise the patient's safety, or put the study outcomes at risk.&#xD;
&#xD;
          4. Less than 2 previous cancer treatments, including high dose chemotherapy and ASCT, for&#xD;
             NHL unless patient refuses standard therapy and/or is not eligible for ASCT.&#xD;
&#xD;
          5. Have significant, uncontrolled, or active cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Tabernero Head, Medical Oncology Department, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vall d' Hebron Institute of Oncology (VHIO) P. Vall d'Hebron 119-129 08035 Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Barcelona Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Madrid. Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCCC Clinical Trials Pharmacy, Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>MEN1309</keyword>
  <keyword>CD205</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>R-R NHL</keyword>
  <keyword>ADC</keyword>
  <keyword>Antibody-Drug Coniugate</keyword>
  <keyword>Metastatic Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03403725/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03403725/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>It was planned to perform this study in 7 sites across 4 European countries: Spain, Italy, Belgium, and UK. Patients were only recruited in 5 sites (3 ES, 1 IT1, 1 BE) prior to the study being stopped. The study started in date 28 August 2017 (FPI) to 19 November 2019 (LPLV). Study Termination letter was sent to authorities on 08 January 2020.</recruitment_details>
      <pre_assignment_details>Male or female patients aged ≥ 18 years. For Step 1 of the study, patients with diagnosis of advanced or metastatic solid tumor. For Step 2, patients with histologically confirmed diagnosis of relapsed or refractory NHL. In both Steps the tumor need to have a positivity (≥ 1+ IHC staining) for CD205.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P2">
          <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P3">
          <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P4">
          <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P5">
          <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P6">
          <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P7">
          <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P8">
          <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P9">
          <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P10">
          <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
        </group>
        <group group_id="P11">
          <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
          <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 0.05mg/kg of MEN1309.</description>
        </group>
        <group group_id="B2">
          <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 0.10mg/kg of MEN1309.</description>
        </group>
        <group group_id="B3">
          <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 0.20mg/kg of MEN1309.</description>
        </group>
        <group group_id="B4">
          <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 0.40mg/kg of MEN1309.</description>
        </group>
        <group group_id="B5">
          <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 0.80mg/kg of MEN1309.</description>
        </group>
        <group group_id="B6">
          <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 1.60mg/kg of MEN1309.</description>
        </group>
        <group group_id="B7">
          <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 2.40mg/kg of MEN1309.</description>
        </group>
        <group group_id="B8">
          <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 3.36mg/kg of MEN1309.</description>
        </group>
        <group group_id="B9">
          <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 2.40mg/kg of MEN1309.</description>
        </group>
        <group group_id="B10">
          <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-positive advanced solid tumors, who recieved 2.00mg/kg of MEN1309.</description>
        </group>
        <group group_id="B11">
          <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
          <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved 0.80mg/kg of MEN1309.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="1"/>
            <count group_id="B12" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.10" spread="0"/>
                    <measurement group_id="B2" value="56.80" spread="0"/>
                    <measurement group_id="B3" value="60.60" spread="0"/>
                    <measurement group_id="B4" value="62.50" spread="0"/>
                    <measurement group_id="B5" value="53.50" spread="0"/>
                    <measurement group_id="B6" value="64.27" spread="17.382"/>
                    <measurement group_id="B7" value="67.30" spread="15.725"/>
                    <measurement group_id="B8" value="61.17" spread="8.520"/>
                    <measurement group_id="B9" value="76.57" spread="15.584"/>
                    <measurement group_id="B10" value="64.55" spread="8.805"/>
                    <measurement group_id="B11" value="109.4" spread="0"/>
                    <measurement group_id="B12" value="66.68" spread="12.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-Tolerated Dose (MTD)</title>
        <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences a DLT during the DLT assessment window.</description>
        <time_frame>21-day period after the first dose</time_frame>
        <population>MTD was evaluated only in the STEP 1 since in STEP 2 only one patient was treated.</population>
        <group_list>
          <group group_id="O1">
            <title>All Doses STEP 1-Solid Tumors</title>
            <description>All Patients with CD205-positive advanced solid tumors inlcuded in STEP1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-Tolerated Dose (MTD)</title>
          <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences a DLT during the DLT assessment window.</description>
          <population>MTD was evaluated only in the STEP 1 since in STEP 2 only one patient was treated.</population>
          <units>mg/Kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Limiting Toxicity (DLT)</title>
        <description>Adverse drug reactions (ADRs) that will be assessed during Cycle 1:&#xD;
any grade ≥ 3 cardiac toxicity, new segmental wall-motion abnormalities, or cardiac troponin I or T elevation of grade 3 or higher;&#xD;
any grade ≥ 3 elevations in total bilirubin, hepatic transaminases, or ALP levels; in patients with baseline grade 2 hepatic transaminase or ALP levels, an elevation to ≥ 10 x ULN is considered a DLT;&#xD;
any grade 3 non-haematologic toxicity lasting &gt; 7 days, (excluding diarrhea/nausea for which no adequate and optimal therapy has been implemented and alopecia);&#xD;
any grade 3 vomiting lasting &gt; 3 days despite adequate and optimal therapy;&#xD;
any grade ≥ 4 non-haematologic toxicity;&#xD;
any grade 4 thrombocytopenia or anemia;&#xD;
any grade 4 neutropenia lasting &gt; 7 days or febrile neutropenia;&#xD;
any treatment delay of &gt; 2 weeks because of delayed recovery from toxicity related to MEN1309 (except for alopecia).</description>
        <time_frame>21-day period after the first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Limiting Toxicity (DLT)</title>
          <description>Adverse drug reactions (ADRs) that will be assessed during Cycle 1:&#xD;
any grade ≥ 3 cardiac toxicity, new segmental wall-motion abnormalities, or cardiac troponin I or T elevation of grade 3 or higher;&#xD;
any grade ≥ 3 elevations in total bilirubin, hepatic transaminases, or ALP levels; in patients with baseline grade 2 hepatic transaminase or ALP levels, an elevation to ≥ 10 x ULN is considered a DLT;&#xD;
any grade 3 non-haematologic toxicity lasting &gt; 7 days, (excluding diarrhea/nausea for which no adequate and optimal therapy has been implemented and alopecia);&#xD;
any grade 3 vomiting lasting &gt; 3 days despite adequate and optimal therapy;&#xD;
any grade ≥ 4 non-haematologic toxicity;&#xD;
any grade 4 thrombocytopenia or anemia;&#xD;
any grade 4 neutropenia lasting &gt; 7 days or febrile neutropenia;&#xD;
any treatment delay of &gt; 2 weeks because of delayed recovery from toxicity related to MEN1309 (except for alopecia).</description>
          <units>Dose Limiting Toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Timeframe between the first study drug administration and death from any cause.</description>
        <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
        <population>For Cohorts reported as 0 analyzed the patients were censored (Event Date Not available)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Timeframe between the first study drug administration and death from any cause.</description>
          <population>For Cohorts reported as 0 analyzed the patients were censored (Event Date Not available)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="379" spread="0"/>
                    <measurement group_id="O3" value="700" spread="0"/>
                    <measurement group_id="O5" value="74" spread="0"/>
                    <measurement group_id="O6" value="154" spread="0"/>
                    <measurement group_id="O7" value="297.75" spread="208.73"/>
                    <measurement group_id="O10" value="90.33" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>The Number of days between the first study administration to the date of first documented disease progression.</description>
        <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
        <population>For Cohorts reported as 0 analyzed the patients were censored (Event Date Not available)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>The Number of days between the first study administration to the date of first documented disease progression.</description>
          <population>For Cohorts reported as 0 analyzed the patients were censored (Event Date Not available)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="41" spread="0"/>
                    <measurement group_id="O5" value="38" spread="0"/>
                    <measurement group_id="O6" value="36.5" spread="0.71"/>
                    <measurement group_id="O7" value="155.5" spread="190.51"/>
                    <measurement group_id="O9" value="100.5" spread="28.99"/>
                    <measurement group_id="O10" value="37" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Tumor Activity (RR)</title>
        <description>Preliminary tumor activity (RR) Response Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
        <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
        <population>Efficacy Population:All eligible patients who receive at least 2 complete treatment cycles and have at least 1 disease assessment are to be considered evaluable for efficacy.&#xD;
The percentage of patient is 0% since no patient had Complete response or partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Preliminary Tumor Activity (RR)</title>
          <description>Preliminary tumor activity (RR) Response Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
          <population>Efficacy Population:All eligible patients who receive at least 2 complete treatment cycles and have at least 1 disease assessment are to be considered evaluable for efficacy.&#xD;
The percentage of patient is 0% since no patient had Complete response or partial response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Antitumor Activity (DCR)</title>
        <description>Preliminary Antitumor Activity (DCR) Disease control Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
        <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
        <population>Efficacy Population:All eligible patients who receive at least 2 complete treatment cycles and have at least 1 disease assessment are to be considered evaluable for efficacy.&#xD;
Out of 11 evaluable patients, 11 patients had stable disease (SD), no complete response or partial response was observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Preliminary Antitumor Activity (DCR)</title>
          <description>Preliminary Antitumor Activity (DCR) Disease control Rate. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
          <population>Efficacy Population:All eligible patients who receive at least 2 complete treatment cycles and have at least 1 disease assessment are to be considered evaluable for efficacy.&#xD;
Out of 11 evaluable patients, 11 patients had stable disease (SD), no complete response or partial response was observed.</population>
          <units>N. of Stable Disease/N. of Pts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O7" value="0.33"/>
                    <measurement group_id="O8" value="0.8"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preliminary Antitumor Activity (DOR)</title>
        <description>Prliminary Antitumor Activity. Measure of the Duration of response. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
        <time_frame>From Day1Visit1 to End of the treatment (At Baseline no more than 6 weeks before treatment and then every cycle starting from cycle 3 until End of Study)</time_frame>
        <population>Data Cannot be reported since it was not analyzed. No Patients had Complete response and Partial Response.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>Preliminary Antitumor Activity (DOR)</title>
          <description>Prliminary Antitumor Activity. Measure of the Duration of response. RECIST v 1.1 assessment was performed using CT or MRI scan of the chest and abdomen (including adrenal glands). For the baseline assessment, CT or MRI scan were to be performed no more than 6 weeks (4+2 weeks) before the treatment start. Follow-up assessment were performed every other cycle starting from cycle 3 until the End of Study Visit.</description>
          <population>Data Cannot be reported since it was not analyzed. No Patients had Complete response and Partial Response.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 PK Parameter Cmax</title>
        <description>Cmax is the maximum drug concentration</description>
        <time_frame>Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 PK Parameter Cmax</title>
          <description>Cmax is the maximum drug concentration</description>
          <units>microgram/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.19"/>
                    <measurement group_id="O2" value="0.87" spread="0.16"/>
                    <measurement group_id="O3" value="1.75" spread="0.09"/>
                    <measurement group_id="O4" value="3.16" spread="0"/>
                    <measurement group_id="O5" value="9.67" spread="2.03"/>
                    <measurement group_id="O6" value="31.87" spread="9.11"/>
                    <measurement group_id="O7" value="43.94" spread="11.25"/>
                    <measurement group_id="O8" value="64.97" spread="33.40"/>
                    <measurement group_id="O9" value="44.50" spread="15.79"/>
                    <measurement group_id="O10" value="33.52" spread="9.29"/>
                    <measurement group_id="O11" value="11.36" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 PK Parameter Ctrough</title>
        <description>MEN1309 PK parameter Ctrough (Predose concentration)</description>
        <time_frame>Pre-infusion Cycle 2</time_frame>
        <population>For Cohort 4 the treatment ended at Cycle 1 for the only subejct.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 PK Parameter Ctrough</title>
          <description>MEN1309 PK parameter Ctrough (Predose concentration)</description>
          <population>For Cohort 4 the treatment ended at Cycle 1 for the only subejct.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0"/>
                    <measurement group_id="O10" value="0" spread="0"/>
                    <measurement group_id="O11" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 Pharmacokinetic (PK) Parameter t1/2</title>
        <description>MEN1309 Pharmacokinetic (PK) parameter t1/2 (terminal serum half-life)</description>
        <time_frame>Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 Pharmacokinetic (PK) Parameter t1/2</title>
          <description>MEN1309 Pharmacokinetic (PK) parameter t1/2 (terminal serum half-life)</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0"/>
                    <measurement group_id="O2" value="3.17" spread="0"/>
                    <measurement group_id="O3" value="2.38" spread="0"/>
                    <measurement group_id="O4" value="16.65" spread="0"/>
                    <measurement group_id="O5" value="93.90" spread="0"/>
                    <measurement group_id="O6" value="18.24" spread="6.49"/>
                    <measurement group_id="O7" value="16.89" spread="1.67"/>
                    <measurement group_id="O8" value="27.74" spread="2.36"/>
                    <measurement group_id="O9" value="15.36" spread="0.96"/>
                    <measurement group_id="O10" value="17.24" spread="1.24"/>
                    <measurement group_id="O11" value="15.08" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 Pharmacokinetic (PK) Parameter AUC</title>
        <description>MEN1309 Pharmacokinetic (PK) parameter AUC (area under curve)</description>
        <time_frame>Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 Pharmacokinetic (PK) Parameter AUC</title>
          <description>MEN1309 Pharmacokinetic (PK) parameter AUC (area under curve)</description>
          <units>hr * microgram/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="0"/>
                    <measurement group_id="O2" value="3.78" spread="0"/>
                    <measurement group_id="O3" value="6.16" spread="0"/>
                    <measurement group_id="O4" value="11.86" spread="0"/>
                    <measurement group_id="O5" value="57.49" spread="0"/>
                    <measurement group_id="O6" value="583.38" spread="213.45"/>
                    <measurement group_id="O7" value="1038.12" spread="257.12"/>
                    <measurement group_id="O8" value="2045.41" spread="1130.69"/>
                    <measurement group_id="O9" value="958.94" spread="417.06"/>
                    <measurement group_id="O10" value="689.33" spread="295.50"/>
                    <measurement group_id="O11" value="111.44" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 (PK) Parameter CL</title>
        <description>Systemic clearance of MEN1309 Pharmacokinetic</description>
        <time_frame>Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 (PK) Parameter CL</title>
          <description>Systemic clearance of MEN1309 Pharmacokinetic</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0"/>
                    <measurement group_id="O2" value="1.46" spread="0"/>
                    <measurement group_id="O3" value="1.96" spread="0"/>
                    <measurement group_id="O4" value="2.06" spread="0"/>
                    <measurement group_id="O5" value="0.70" spread="0"/>
                    <measurement group_id="O6" value="0.20" spread="0.09"/>
                    <measurement group_id="O7" value="0.17" spread="0.08"/>
                    <measurement group_id="O8" value="0.13" spread="0.9"/>
                    <measurement group_id="O9" value="0.21" spread="0.07"/>
                    <measurement group_id="O10" value="0.22" spread="0.11"/>
                    <measurement group_id="O11" value="0.78" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MEN1309 Pharmacokinetic (PK) Parameter Vd</title>
        <description>volume of distribution based on the terminal phase</description>
        <time_frame>Cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.05 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O2">
            <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.10 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O3">
            <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.20 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O4">
            <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O5">
            <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O6">
            <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 1.60 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O7">
            <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O8">
            <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 3.36 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O9">
            <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.40 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O10">
            <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
            <description>Patients with CD205-positive advanced solid tumors, who recieved a dose of 2.00 mg/Kg of MEN1309.</description>
          </group>
          <group group_id="O11">
            <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
            <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved a dose of 0.80 mg/Kg of MEN1309.</description>
          </group>
        </group_list>
        <measure>
          <title>MEN1309 Pharmacokinetic (PK) Parameter Vd</title>
          <description>volume of distribution based on the terminal phase</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="0"/>
                    <measurement group_id="O2" value="6.69" spread="0"/>
                    <measurement group_id="O3" value="6.73" spread="0"/>
                    <measurement group_id="O4" value="49.47" spread="0"/>
                    <measurement group_id="O5" value="95.45" spread="0"/>
                    <measurement group_id="O6" value="4.97" spread="2.5"/>
                    <measurement group_id="O7" value="4.02" spread="1.32"/>
                    <measurement group_id="O8" value="4.73" spread="1.80"/>
                    <measurement group_id="O9" value="5.55" spread="3.24"/>
                    <measurement group_id="O10" value="5.08" spread="3.08"/>
                    <measurement group_id="O11" value="16.94" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of CD205 Expression in Tumors With Clinical Activity of MEN1309 Assessed According to RECIST 1.1 or Cheson Criteria (2014)</title>
        <description>Exploratory Endpoint: Correlation of CD205 expression in tumors with clinical activity of MEN1309 assessed according to RECIST 1.1 or Cheson Criteria (2014) in terms of Response Rate, Disease control rate, duration of response, overall survival, and progression free survival.&#xD;
N.B: No Data were available to assess this outcome.</description>
        <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
        <population>N.B: No Data were available to assess this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>STEP1 Solid Tumor All Doses + STEP 2 NHL</title>
            <description>All Patients with CD205-positive advanced solid tumors inlcuded in STEP1 and all NHL patients included in STEP 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of CD205 Expression in Tumors With Clinical Activity of MEN1309 Assessed According to RECIST 1.1 or Cheson Criteria (2014)</title>
          <description>Exploratory Endpoint: Correlation of CD205 expression in tumors with clinical activity of MEN1309 assessed according to RECIST 1.1 or Cheson Criteria (2014) in terms of Response Rate, Disease control rate, duration of response, overall survival, and progression free survival.&#xD;
N.B: No Data were available to assess this outcome.</description>
          <population>N.B: No Data were available to assess this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Anti-MEN1309 Antibodies</title>
        <description>Exploratory Endpoint: Immunogenicity analysis regarding the Incidence of anti-MEN1309 antibodies.</description>
        <time_frame>Day 1 of each Cycle (each cycle is 21 days)</time_frame>
        <population>For this Outcome Results are not available per Cohorts, but only on the total of patients analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>STEP1 Solid Tumor All Doses + STEP 2 NHL</title>
            <description>All Patients with CD205-positive advanced solid tumors inlcuded in STEP1 and all NHL patients included in STEP 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Anti-MEN1309 Antibodies</title>
          <description>Exploratory Endpoint: Immunogenicity analysis regarding the Incidence of anti-MEN1309 antibodies.</description>
          <population>For this Outcome Results are not available per Cohorts, but only on the total of patients analyzed.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, from &quot;August 28, 2017&quot; to &quot;January 8, 2020&quot; (2 years and 4 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort1 0.05mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 0.05 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E2">
          <title>Cohort2 0.10mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 0.10 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E3">
          <title>Cohort3 0.20mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 0.20 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E4">
          <title>Cohort4 0.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 0.40 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E5">
          <title>Cohort5 0.80mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 0.80 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E6">
          <title>Cohort6 1.60mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 1.60 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E7">
          <title>Cohort7 2.40mg/kg STEP 1 Solid Tumors</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 2.40 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E8">
          <title>Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 3.36 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E9">
          <title>Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 2.40 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E10">
          <title>Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF</title>
          <description>Patients with CD205-advanced Solid Tumor, who recieved 2.00 mg/kg of MEN1309.</description>
        </group>
        <group group_id="E11">
          <title>Cohort5 0.80mg/kg STEP 2 NHL</title>
          <description>Patients with CD205-positive multiple relapsed or refractory Non Hodking Lymphoma, who recieved 0.80mg/kg of MEN1309.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ECOG performance Status Worsened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmunary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adnominal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrooesphageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema Pheripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bliriubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>lymphocyte count decresed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" events="12" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>white blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corporate Director of Clinical Sciences</name_or_title>
      <organization>Menarini Ricerche SPA</organization>
      <phone>+39 055 56809933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

